NCT06161922 2023-12-08
Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
Fudan University
Unknown
Clinical Trials
15 trialsNCT05945368 2023-07-14
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT04288141 2022-11-14
HERdi PREDICT
King's College London
Unknown
NCT05561686 2022-09-30
Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
Hunan Cancer Hospital
Unknown
NCT05429294 2022-06-23
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT05189067 2022-01-12
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3 Unknown
NCT03238495 2021-12-07
HERMET
University of Kansas Medical Center
Phase 2 Unknown
NCT03655353 2021-09-29
Affibody-3
Uppsala University Hospital
Phase NA Unknown
NCT04276337 2020-02-19
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
Samsung Medical Center
Unknown
NCT04034823 2019-07-26
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT04011085 2019-07-08
Tw HER2 Positive Breast Cancer Productivity & Utility Study
Taiwan Epidemiology Association
Unknown
NCT03919253 2019-04-18
Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study
Hebei Medical University Fourth Hospital
Phase 2 Unknown
NCT03881878 2019-03-21
TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery
Samsung Medical Center
Phase 1/2 Unknown
NCT03847818 2019-03-01
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer
Shandong University
Phase NA Unknown
NCT03684863 2018-09-26
Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
Shandong Cancer Hospital and Institute
Phase 2 Unknown